Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease
Shots:
- Innovate Biopharmaceuticals announces the initiation of P-III clinical study of INI-202 for Celiac disease with its expected screening & enrollment updates in next few months
- The P-III clinical study is the one of key event for addressing needs of Celiac patients with continued symptoms despite being on a gluten-free diet
- Innovate focuses on developing therapies for autoimmune and inflammatory diseases including its lead candidate larazotide acetate- renormalizing dysfunctional intestinal barrier by reducing intestinal permeability & antigen trafficking
Ref: Innovate Biopharmaceuticals | Image: University of Virginia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com